These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9873794)

  • 1. Factor VIII inhibitors in mild and moderate-severity haemophilia A.
    Hay CR
    Haemophilia; 1998 Jul; 4(4):558-63. PubMed ID: 9873794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.
    Hay CR; Ludlam CA; Colvin BT; Hill FG; Preston FE; Wasseem N; Bagnall R; Peake IR; Berntorp E; Mauser Bunschoten EP; Fijnvandraat K; Kasper CK; White G; Santagostino E
    Thromb Haemost; 1998 Apr; 79(4):762-6. PubMed ID: 9569189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution.
    van den Brink EN; Timmermans SM; Turenhout EA; Bank CM; Fijnvandraat K; Voorberg J; Peters M
    Thromb Haemost; 1999 May; 81(5):723-6. PubMed ID: 10365744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation.
    Thompson AR; Murphy ME; Liu M; Saenko EL; Healey JF; Lollar P; Scandella D
    Blood; 1997 Sep; 90(5):1902-10. PubMed ID: 9292523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation.
    Bril WS; MacLean PE; Kaijen PH; van den Brink EN; Lardy NM; Fijnvandraat K; Peters M; Voorberg J
    Haemophilia; 2004 Sep; 10(5):509-14. PubMed ID: 15357778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired haemophilia syndrome: pathophysiology and therapy.
    Elezović I
    Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():64-8. PubMed ID: 20229686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Porcine factor VIII provides clinical benefit to patients with high levels of inhibitors to human and porcine factor VIII.
    Gribble J; Garvey MB
    Haemophilia; 2000 Sep; 6(5):482-5. PubMed ID: 11012689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand.
    Lloyd JV; Street AM; Berry E; McPherson J; Ekert H; Lammi A; McWhirter WR; Duncan EM; Maxwell EL; Rowell J; Baker RI; Leahy MF; Jupe D
    Aust N Z J Med; 1997 Dec; 27(6):658-64. PubMed ID: 9483232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The genetic basis of inhibitor development in haemophilia A.
    Tuddenham EG; McVey JH
    Haemophilia; 1998 Jul; 4(4):543-5. PubMed ID: 9873791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitor development in correlation to factor VIII genotypes.
    Oldenburg J; El-Maarri O; Schwaab R
    Haemophilia; 2002 Mar; 8 Suppl 2():23-9. PubMed ID: 11966849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution.
    Rocino A; Papa ML; Salerno E; Capasso F; Miraglia E; de Biasi R
    Haemophilia; 2001 Jan; 7(1):33-8. PubMed ID: 11136378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.
    Scharrer I; Bray GL; Neutzling O
    Haemophilia; 1999 May; 5(3):145-54. PubMed ID: 10444280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired inhibitors.
    Cohen AJ; Kessler CM
    Baillieres Clin Haematol; 1996 Jun; 9(2):331-54. PubMed ID: 8800509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
    Zanon E; Zerbinati P; Girolami B; Bertomoro A; Girolami A
    Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party.
    Hay CR; Colvin BT; Ludlam CA; Hill FG; Preston FE
    Blood Coagul Fibrinolysis; 1996 Mar; 7(2):134-8. PubMed ID: 8735802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.